Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

First LockeT Cases Completed in Germany

By: Catheter Precision, Inc. via GlobeNewswire

August 13, 2025 at 08:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

FORT MILL, S.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that the first LockeT cases were recently completed in Germany at Zentralklinik Bad Berka. With a total of 20 clinics and specialist departments, it is one of the largest hospitals in Thuringia.

To date, the physician team has successfully performed 10 cases, using LockeT to close single or multiple punctures with just one device per case. These procedures have spanned sheath sizes from 6F to 17Fr, demonstrating LockeT’s versatility and reliability.

David Jenkins, CEO of Catheter Precision said, “Germany is one of the largest markets in Europe and price conscious, making LockeT a great solution. As we continue our partnership with Bad Berka, we also look forward to expanding our footprint to other centers in Germany. We extend our sincere thanks to Professor J. Christoph Geller, Dr. Santi Raffa, Dr. Markus Frommhold, who is also the very first user of LockeT in Germany, and Dr. Obaida Alothman for their invaluable support and feedback.”

About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

# # #

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	265.06	-1.26 (-0.47%)
AAPL	308.38	-0.44 (-0.14%)
AMD	503.75	+36.24 (7.75%)
BAC	52.09	+0.30 (0.57%)
GOOG	384.72	+5.34 (1.41%)
META	610.62	+0.36 (0.06%)
MSFT	415.43	-3.14 (-0.75%)
NVDA	214.13	-1.20 (-0.56%)
ORCL	192.06	-0.03 (-0.01%)
TSLA	432.61	+6.60 (1.55%)